IRIS
GNETTI, Letizia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.243
AS - Asia 4.294
EU - Europa 2.887
SA - Sud America 631
AF - Africa 274
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 3
Totale 13.336
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.099
SG - Singapore 1.499
CN - Cina 1.061
IT - Italia 783
VN - Vietnam 708
BR - Brasile 460
IE - Irlanda 438
SE - Svezia 411
HK - Hong Kong 311
DE - Germania 246
BD - Bangladesh 225
FR - Francia 223
ZA - Sudafrica 173
NL - Olanda 122
GB - Regno Unito 114
IN - India 108
RU - Federazione Russa 102
AT - Austria 101
FI - Finlandia 96
CA - Canada 77
TR - Turchia 73
AR - Argentina 68
UA - Ucraina 51
BE - Belgio 45
IQ - Iraq 45
MX - Messico 38
CI - Costa d'Avorio 36
EC - Ecuador 34
JP - Giappone 34
CZ - Repubblica Ceca 31
ID - Indonesia 31
KR - Corea 30
PL - Polonia 30
ES - Italia 28
CO - Colombia 24
PK - Pakistan 23
PH - Filippine 19
UZ - Uzbekistan 16
MA - Marocco 13
LT - Lituania 12
SA - Arabia Saudita 12
VE - Venezuela 12
GR - Grecia 11
IL - Israele 11
KE - Kenya 11
TH - Thailandia 11
CL - Cile 10
EG - Egitto 10
TW - Taiwan 10
KZ - Kazakistan 9
PY - Paraguay 8
TN - Tunisia 8
CH - Svizzera 7
JO - Giordania 7
MY - Malesia 7
AZ - Azerbaigian 6
ET - Etiopia 6
AE - Emirati Arabi Uniti 5
BO - Bolivia 5
AL - Albania 4
AM - Armenia 4
BY - Bielorussia 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
HN - Honduras 4
JM - Giamaica 4
NP - Nepal 4
PA - Panama 4
PE - Perù 4
PS - Palestinian Territory 4
PT - Portogallo 4
CG - Congo 3
CR - Costa Rica 3
DZ - Algeria 3
GY - Guiana 3
HU - Ungheria 3
IR - Iran 3
NG - Nigeria 3
OM - Oman 3
PR - Porto Rico 3
RO - Romania 3
SV - El Salvador 3
UY - Uruguay 3
XK - ???statistics.table.value.countryCode.XK??? 3
AU - Australia 2
BG - Bulgaria 2
BH - Bahrain 2
BW - Botswana 2
GT - Guatemala 2
HR - Croazia 2
KH - Cambogia 2
KW - Kuwait 2
LB - Libano 2
LK - Sri Lanka 2
LV - Lettonia 2
NO - Norvegia 2
RS - Serbia 2
BB - Barbados 1
EU - Europa 1
GD - Grenada 1
Totale 13.320
Salva come PNG Salva come JPEG
Città #
Singapore 831
Ashburn 777
Chandler 552
Dallas 459
San Jose 457
Dublin 434
Santa Clara 321
Hong Kong 298
Beijing 240
Ho Chi Minh City 211
New York 195
Parma 181
Hanoi 179
Boardman 173
Johannesburg 162
Ann Arbor 160
Los Angeles 148
Shanghai 119
Munich 94
Lauterbourg 91
Dearborn 89
Hefei 87
Vienna 86
Chicago 72
Nanjing 69
Princeton 65
Council Bluffs 57
Milan 57
Izmir 44
Moscow 44
São Paulo 41
Rio Saliceto 40
Buffalo 39
Helsinki 39
Jacksonville 39
Brussels 38
Abidjan 35
Bologna 35
Wilmington 35
Jinan 34
Bremen 32
Columbus 32
Haiphong 32
The Dalles 32
Da Nang 31
Seattle 30
Frankfurt am Main 29
Seoul 27
Montreal 26
Marseille 24
Tokyo 24
Chennai 23
Nuremberg 23
Toronto 23
Warsaw 23
Des Moines 22
London 22
Modena 22
Rome 22
Tianjin 22
Atlanta 21
Denver 20
Guangzhou 20
Houston 19
Hebei 18
Kunming 18
Orem 18
Turku 18
San Mateo 17
Changsha 16
Curitiba 16
Jakarta 16
West Jordan 16
Fremont 15
Shenyang 15
Bengaluru 14
Phoenix 14
Rio de Janeiro 14
Tashkent 14
Brno 13
Brooklyn 13
Reggio Emilia 13
San Francisco 13
Stockholm 13
Baghdad 12
Belo Horizonte 12
Boston 12
Hải Dương 12
Poplar 12
Quito 12
Redondo Beach 12
Erbil 11
Jiaxing 11
Lahore 11
Mexico City 11
Nairobi 11
Redwood City 11
Amsterdam 10
Athens 10
Brescia 10
Totale 8.212
Salva come PNG Salva come JPEG
Nome #
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 247
Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patients 213
Isolation and characterization of circulating tumor cells in advanced squamous-cell carcinoma of the lung 207
Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab 204
227P Sexual dimorphism in immune profile of early and advanced NSCLC 202
High levels of Notch intracellular cleaved domain are associated with stemness and reduced bevacizumab efficacy in patients with advanced colon cancer 200
Notch-Jagged1 signaling and response to bevacizumab therapy in advanced colorectal cancer: A glance to radiomics or back to physiopathology? 194
INTEGRATION OF TISSUE PD-1/PD-L1 IMMUNE CHECKPOINT WITH COMPUTED TOMOGRAPHY (CT) BASED TEXTURE ANALYSIS EXHIBITS HIGH PROGNOSTIC IMPACE ON SURGICALLY RESECTED NON SMALL CELL LUNG CANCER (NSCLC) 194
Solid-phase microextraction coupled to gas chromatography mass spectrometry followed by multivariate data analysis for the identification of volatile organic compounds as possible biomarkers in lung cancer tissues 194
Blood and lymphatic vessels contribute to the impact of the immune microenvironment on clinical outcome in non-small-cell lung cancer 191
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 190
MESENCHYMAL STROMAL CELLS ISOLATED FROM DEFINED NSCLC CONTEXTURES REPRODUCE THE IMMUNE SIGNATURE OF THE PARENTAL MICROENVIRONMENT 182
PREDICTIVE AND PROGNOSTIC VALUE OF CLINICAL AND MOLECULAR FEATURES IN PATIENTS UNDERGOING PULMONARY METASTASECTOMY FROM RENAL CELL CARCINOMA 182
Leiomioma metastatizzante benigno gigante 180
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 178
Pili canaliculi: a familial study 177
Early fetal akinesia sequence: A case report with unusual autoptic features 175
Human Papilloma Virus (HPV) status, P16INK4a and p53 overexpression in epithelial malignant and borderline ovarian neoplasms 173
Dataset on the identification of a prognostic radio-immune signature in surgically resected Non Small Cell Lung Cancer 173
Pulmonary metastasectomy for colorectal cancer: Analysis of prognostic factors affecting survival 171
A pulmonary infection by Actinomyces odontolyticus and Veillonella atypica in an immunocompetent patient with dental caries 171
Endometrial mucinous microglandular adenocarcinoma: morphologic, immunohistochemical features and emphasis in the HPV status 170
Pleural tuberculosis: medical thoracoscopy greatly increases the diagnostic accuracy 168
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 167
Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: A case report 167
The role of miRNA-221 and miRNA-126 in patients with benign metastasizing leiomyoma of the lung: an overview with new interesting scenarios 165
Kidney Biopsy Findings in a Critically Ill COVID-19 Patient With Dialysis-Dependent Acute Kidney Injury: A Case Against “SARS-CoV-2 Nephropathy 163
Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial 163
Computed tomography - histology correlations of unusual lung tumors 162
Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature 162
Widespread Nivolumab-induced Enteropathy in a Long Responder Non–Small-cell Lung Cancer Patient 161
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 157
Prognostic value of [18F]FDG PET/CT parameters in surgically resected primary lung adenocarcinoma: a single-center experience 156
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 155
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 154
Spatial architecture of tumour-infiltrating lymphocytes as a prognostic parameter in resected non-small-cell lung cancer 152
Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors 151
Integrated CT imaging and tissue immune features disclose a radio-immune signature with high prognostic impact on surgically resected NSCLC 151
Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneity 149
The prognostic value of the haemoglobin/red cell distribution width ratio in a cohort of pre-treated patients with renal cell carcinoma receiving nivolumab 148
A case of Solitary fibrous pleura tumor associated with severe hypoglycemia: the Doege-Potter 's Syndrome 148
KRAS: A Druggable Target in Colon Cancer Patients 148
Multiple primary malignancies involving lung cancer: a single-center experience 147
Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma 146
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC 145
Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs) 142
Onset of ANCA-positive EGPA with bilateral pleural effusion: a case report 141
Monitoring cfDNA in plasma and in other liquid biopsies of advanced EGFR mutated NSCLC patients: A pilot study and a review of the literature 139
Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib 137
Relationship Between the Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) and Lung Adenocarcinoma Patterns: New Possible Insights 136
EXCEPTIONAL EVOLUTION OF BENIGN METASTASIZING LEIOMYOMAS OF THE LUNG 135
Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) Syndrome and Carcinoid Tumors With/Without NECH: A Clinicopathologic, Radiologic, and Immunomolecular Comparison Study 135
Testicular metastasis of prostate adenocarcinoma: the other side of orchiepididymitis 132
Giant intercostal nerve schwannoma in a patient with neurofibromatosis type 2 132
Optimizing PD-L1 evaluation on cytological samples from advanced non-small-cell lung cancer 132
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC 131
METACHRONOUS AND SYNCHRONOUS OCCURRENCE OF PRIMARY MALIGNANCIES IN PATIENTS WITH RESECTED NON SMALL CELL LUNG CANCER (NSCLC): A RETROSPECTIVE OBSERVATIONAL STUDY 129
YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs 129
Primary atypical carcinoid tumor of the mediastinum: A very rare finding 127
TUMOR-INFILTRATING LYMPHOCYTES, PDL-1, BAP-1, VEGFR-2 AND IGF-1R EXPRESSION IN MALIGNANT PLEURAL MESOTHELIOMA 127
CD26 is differentially expressed throughout the life cycle of infantile hemangiomas and characterizes the proliferative phase 126
SURGICAL SAMPLING IS AN EMERGING ISSUE IN THE ASSESSMENT OF THE IMMUNE CONTEXTURE IN NON SMALL CELL LUNG CANCER (NSCLC) 125
Vulvar acantholytic squamous carcinoma: a case report with immunohistochemical and molecular study. 124
GIANT PRIMARY DEDIFFERENTIATED LIPOSARCOMA OF THE ANTERIOR MEDIASTINUM: AN EXTREMELY RARE OCCURRENCE 121
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy 121
Tubercolosi pleurica multi-resistente in gravidanza: Challenge diagnostico e terapeutico 118
Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review 118
Role of human papillomavirus in the development of epithelial ovarian neoplasms in Italian women 118
Abscopal effect after hypofractionated radiotherapy in metastatic renal cell carcinoma pretreated with pazopanib 116
Oncocytic mucoepidermoid carcinoma of a submandibular gland: a case report and review of the literature. 115
Cryptogenic Fibrosing Pleuritis 112
L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC 112
7P STK11 and Galectin-3 tissue expression entails a prognostic signature in immunotherapy treated NSCLC patients 110
Lung Manifestation of IgG4-related Disease. A multifaceted disorder. Presentation of two cases and short review of literature 107
Retroperitoneal cystoadenocarcinoma: A case report with a literature review 107
Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy 104
MET alterations as resistance mechanisms of dabrafenib-trametinib in BRAF p.V600E mutated non-small cell lung cancer patient 102
Spread through air spaces in lung adenocarcinoma: Is radiology reliable yet? 102
Influence of preoperative chemoradiation on tumor-infiltrating lymphocytes in locally advanced rectal cancer: The STAR-01 cohort 101
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers 101
Activity of lenvatinib plus everolimus combination in a heavily pretreated patient with papillary renal cell carcinoma: a case report 101
Very late recurrence of an apparently benign pheochromocytoma 98
Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study 97
Influence of preoperative chemoradiation on tumor-infiltrating lymphocytes in locally advanced rectal cancer: The STAR-01 cohort 94
Impact of preoperative chemoradiotherapy on tumor infiltrating lymphocytes in locally advanced rectal cancer: The SMART-STAR study 93
Malignant deciduoid pleural mesothelioma: A case report 93
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators 92
Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC 92
MicroRNA Expression in Malignant Pleural Mesothelioma and Asbestosis: A Pilot Study 91
BRAF Fusion as Resistance Mechanism to Osimertinib in EGFR-Mutated NSCLC: A Case Report and Review of Literature 89
Prognostic impact of lung adenocarcinoma second predominant pattern from a large European database 89
SOLITARY FIBROUS TUMOR OF THE PLEURA ASSOCIATED WITH SEVERE HYPOGLICEMIA: THE DOEGE-POTTER SYNDROME 85
Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review 83
Plasma exchange-sensitive syncytial glomerulopathy in a kidney transplant patient 69
Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring BRAF Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups 68
Identification of a radio-immune signature with high prognostic value in surgically resected NSCLC 66
Genetic, tissue and circulating PD-L1 profiling to predict the response to immuno-checkpoint inhibitors in advanced NSCLC 58
Multiple targets, germline BRCA1 mutation and HRD in a lung cancer patient: Molecular considerations and treatment decision-making 53
Totale 13.528
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.800
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.800
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202123 0 0 0 0 0 0 0 0 0 0 0 23
2021/2022403 22 13 5 18 8 13 76 27 20 31 25 145
2022/20231.828 168 240 106 151 151 222 24 125 522 14 76 29
2023/2024841 32 68 14 31 48 176 82 51 50 74 66 149
2024/20252.551 97 124 177 170 271 254 154 125 239 252 223 465
2025/20266.475 555 502 876 688 829 397 592 244 776 440 399 177
Totale 13.528